Molecular deciphering of the ABO system as a basis for novel diagnostics and therapeutics in ABO incompatible transplantation

International Reviews of Immunology

Volumn 33, Issue 3, 2014, Pages 174-194

  Holgersson, Jan ^a   Rydberg, Lennart ^a   Breimer, Michael E ^b  

^a Department of Surgery or Jan Holgersson Department of Clinical Chemistry Transfusion Medicine ^*  (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

ABO blood group system; Blood group ABH antigens; Blood group ABO antibodies; Carbohydrate antigens; Glycoengineering; Mucins; Transplantation

Indexed keywords

ANTIBODY; BLOOD GROUP ABH ANTIGEN; EPITOPE; HLA ANTIGEN; BLOOD GROUP ABO SYSTEM;

ANTIBODY TITER; ANTIGEN SPECIFICITY; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP ABO SYSTEM; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMAGGLUTINATION; HUMAN; IMMUNOADSORPTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION; XENOTRANSPLANTATION; BLOOD GROUP INCOMPATIBILITY; DESENSITIZATION; GRAFT REJECTION; IMMUNOLOGY; ORGAN TRANSPLANTATION; PROCEDURES; TRENDS;

ABO BLOOD-GROUP SYSTEM; BLOOD GROUP INCOMPATIBILITY; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; ORGAN TRANSPLANTATION;

EID: 84900860310     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2013.857408     Document Type: Review

References (170)

1. Matevossian E, Kern H, Huser N, et al. Surgeon Yurii Voronoy (1895-1961)-a pioneer in the history of clinical transplantation: in memoriam at the 75th anniversary of the first human kidney transplantation. Transplant Int 2009;22:1132-1139.
2. Cook DJ, Graver B, Terasaki PI. ABO incompatibility in cadaver donor kidney allografts. Transplant Proc 1987;19:4549-4552. (Pubitemid 18049659)
3. Brynger H, Blohme I, Lindholm A, et al. Transplantation of Cadaver Kidneys from Blood Group-A2 Donors. Transplant Proc 1982;14:195. (Pubitemid 12079798)
4. Rydberg L, Breimer ME, Samuelsson BE, et al. Blood group ABO-incompatible (A2 to O) kidney transplantation in human subjects: a clinical, serologic, and biochemical approach. Transplantation Proc 1987;19:4528-4537. (Pubitemid 18049655)
5. AlexandreGPJ, Squifflet JP, Debruyere M, et al. Splenectomy as a Prerequisite for SuccessfulHuman Abo-Incompatible Renal-Transplantation. Transplant Proc 1985;17:138-143. (Pubitemid 15170770)
6. Alexandre GP, Squifflet JP, De Bruyere M, et al. Present experiences in a series of 26 ABOincompatible living donor renal allografts. Transplant Proc 1987;19:4538-4542. (Pubitemid 18049656)
7. Squifflet J-P, De Meyer M, Malaise J, et al. Lessons learned from ABO-incompatible living donor kidney transplantation: 20 years later. Exp Clin Transplant 2004;2:208-213.
8. Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003;75:971-977. (Pubitemid 36438524)
9. SlapakM, Digard N, Ahmed M, et al. Renal transplantation across the ABO barrier-a 9-year experience. Transplant Proc 1990;22:1425-1428. (Pubitemid 20284379)
10. Tanabe K, Takahashi K, Sonda K, et al. Long-termresults of ABO-incompatible living kidney transplantation: a single-center experience. Transplantation 1998;65:224-228. (Pubitemid 28101328)
11. Fryer JP, Benedetti E, Perry EH, et al. Antibody-mediated rejection of an HLA-identical, ABO-incompatible kidney transplant after two failed cadaver transplants. Transplantation 1994;58:723-725. (Pubitemid 24317774)
12. Hanto DW, Brunt EM, Goss JA, et al. Accelerated acute rejection of an A2 renal allograft in an O recipient: association with an increase in anti-A2 antibodies. Transplantation 1993;56:1580-1583. (Pubitemid 24018839)
13. Alexander JW, First MR, Majeski JA, et al. The late adverse effect of splenectomy on patient survival following cadaveric renal transplantation. Transplantation 1984;37:467-470. (Pubitemid 14119046)
14. Sutherland DE, Fryd DS, So SK, et al. Long-term effect of splenectomy versus no splenectomy in renal transplant patients. Reanalysis of a randomized prospective study. Transplantation 1984;38:619-624. (Pubitemid 15183468)
15. Takahashi K, Saito K, Tanabe K, et al. First report of a 7-year survey on ABO-incompatible kidney transplantation in Japan. Clin Exp Nephrol 2001;5:119-125. (Pubitemid 32675039)
16. Takahashi K, Saito K, Takahara S, et al. Japanese ABOIKTC. Excellent long-term outcome of ABOincompatible living donor kidney transplantation in Japan. AmJ Transplant 2004;4:1089-1096. (Pubitemid 38868599)
17. Norden G, Briggs D, Cockwell P, et al. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment. Xenotransplantation 2006;13:148-153.
18. Tyden G, Kumlien G, GenbergH, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005;5:145- 148. (Pubitemid 40095139)
19. Rydberg L, Ascher H, Krantz M, et al. Characterization of the humoral immune response in two paediatric patients transplantedwith split livers fromABO-incompatible living-related donors: appearance of cytomegalovirus- induced ABO antibodies. TransfusMed 2005;15:137-144. (Pubitemid 40663545)
20. Donauer J, Wilpert J, Geyer M, et al. ABO-incompatible kidney transplantation using antigenspecific immunoadsorption and rituximab: a single center experience. Xenotransplantation 2006;13:108-110.
21. Tyden G. The European experience Transplantation 2007 84:S2-S3.
22. Flint SM, Walker RG, Hogan C, et al. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression. AmJ Transplant 2011;11:1016-1024.
23. Saito K, Nakagawa Y, Suwa M, et al. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplantation 2006;13:111-117.
24. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004;4:1315-1322. (Pubitemid 39013579)
25. Gordon RD, Iwatsuki S, Esquivel CO, et al. Liver transplantation across ABO blood groups. Surgery 1986;100:342-348. (Pubitemid 16037556)
26. Gugenheim J, Samuel D, Reynes M, et al. Liver transplantation across AB0 blood group barriers. Lancet 1990;336:519-523. (Pubitemid 20278096)
27. Fishbein TM, Emre S, Guy SR, et al. Safe transplantation of blood type A2 livers to blood type O recipients. Transplantation 1999;67:1071-1073. (Pubitemid 29200863)
28. Kluger MD, Guarrera JV, Olsen SK, et al. Safety of blood group A2-to-O liver transplantation: an analysis of the United Network of Organ Sharing database. Transplantation 2012;94:526-531.
29. Skogsberg U, Breimer ME, Friman S, et al. Successful ABO-incompatible liver transplantation using A2 donors. Transplant Proc 2006;38:2667-2670. (Pubitemid 44693642)
30. Banner NR, Rose ML, Cummins D, et al. Management of an ABO-incompatible lung transplant. Am J Transplant 2004;4:1192-1196.
31. Struber M, Warnecke G, Hafer C, et al. Intentional ABO-incompatible lung transplantation. Am J Transplant 2008;8:2476-2478.
32. West LJ, Pollock-Barziv SM, Dipchand AI, et al. ABO-incompatible heart transplantation in infants. N Engl J Med 2001;344:793-800. (Pubitemid 32222156)
33. Biglarnia AR, Nilsson B, Nilsson T, et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transplant Int 2011;24:e61-e66.
34. Daniels G. ABO, Hh and Lewis Blood Group Systems. Human blood groups. Oxford, UK: Blackwell Science Ltd; 1995.
35. Economidou J, Hughes-Jones NC, Gardner B. Quantitative measurements concerning A and B antigen sites. Vox Sang 1967;12:321-328.
36. Holgersson J, Breimer ME, Samuelsson BE. Basic biochemistry of cell surface carbohydrates and aspects of the tissue distribution of histo-blood group ABH and related glycosphingolipids. APMIS Suppl 1992;27:18-27.
37. Breimer ME, Molne J, Norden G, et al. Blood group A and B antigen expression in human kidneys correlated to A1/A2/B, Lewis, and secretor status. Transplantation 2006;82:479-485. (Pubitemid 44290253)
38. Breimer ME, Samuelsson BE. The specific distribution of glycolipid-based blood group A antigens inhumankidney related to A1/A2, Lewis, and secretor status of single individuals. Apossiblemolecular explanation for the successful transplantation of A2 kidneys into O recipients Transplantation 1986 42 88-91
39. Ulfvin A, Bäcker AE, Clausen H, et al. Expression of glycolipid blood group antigens in single human kidneys: change in antigen expression of rejected ABO incompatible kidney grafts. Kidney Int 1993;44:1289-1297. (Pubitemid 23353311)
40. Holgersson J, Backer AE, Breimer ME, et al. The blood group B type-4 heptaglycosylceramide is a minor blood group B structure in human B kidneys in contrast to the corresponding A type- 4 compound in A kidneys. Structural and in vitro biosynthetic studies. Biochim Biophys Acta 1992;1180:33-43.
41. KleinHG, Anstee DJ. ABO, Lewis and P groups and Ii antigens.Mollison's blood transfusion in clinical medicine. 11th ed. Oxford, UK: Blackwell Publishing; 2005. pp. 114-162.
42. Bryan CF, Nelson PW, Aeder MI, et al. Current experience with renal transplantation across the ABO blood group barrier. Transplant Proc 1992;24:2527-2529. (Pubitemid 23011582)
43. Shimmura H, Tanabe K, Ishikawa N, et al. Role of anti-A/B antibody titers in results of ABO incompatible kidney transplantation. Transplantation 2000;70:1331-1335.
44. Kumlien G, Wilpert J, Safwenberg J, et al. Comparing the tube and gel techniques for ABO antibody titration, as performed in three European centers. Transplantation 2007;84:S17-S19.
45. Tanabe K. Interinstitutional variation in the measurement of anti-A/B antibodies: the Japanese ABO-Incompatible Transplantation Committee survey. Transplantation 2007;84:S13-S16.
46. Tyden G, Kumlien G, Efvergren M. Present techniques for antibody removal. Transplantation 2007;84:S27-S29.
47. Rydberg L, Bengtsson A, Samuelsson O, et al. In vitro assessment of a new ABO immunosorbent with synthetic carbohydrates attached to sepharose. Transplant Int 2005;17:666-672. (Pubitemid 40558223)
48. Biglarnia AR, Nilsson B, Nilsson Ekdahl K, et al. Desensitization with antigen-specific immunoadsorption interferes with complement in ABO-incompatible kidney transplantation. Transplantation 2012;93:87-92.
49. Valli PV, Puga Yung G, Fehr T, et al. Changes of circulating antibody levels induced by ABO antibody adsorption for ABO-incompatible kidney transplantation. Am J Transplant 2009;9:1072-1080.
50. Mannami M, Mitsuhata N. Improved outcomes after ABO-incompatible living-donor kidney transplantation after 4 weeks of treatment with mycophenolate mofetil. Transplantation 2005;79:1756-1758. (Pubitemid 40885277)
51. Agishi T, Takahashi K, Ota K, et al. Comparative evalutation of immunoadsorption and double filtration plasmapheresis for removal of anti-A or anti-B antibody in ABO-incompatible kidney transplantation. Transplant Proc 1992;24:557-558.
52. Rydberg L, Hallberg E, Björck S, et al. Studies on the removal of anti-pig xenoantibodies in the human by plasmapheresis/immunoadsorption. Xenotransplantation 1995;2:253-263. (Pubitemid 3013283)
53. Dorling A Transplant accomodation - are the lessons learned from xenotransplantation pertinent for clinical allotransplantation? Am J Transplant 2012 12 545-553
54. Lynch RJ, Platt JL. Accommodation in organ transplantation. Curr Opin Organ Transplant 2008;13:165-170. (Pubitemid 351374255)
55. Lynch RJ, Platt JL. Accommodation in renal transplantation: unanswered questions. Curr Opin Organ Transplant 2010;15:481-485.
56. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990;11:450-456.
57. Alkhunaizi AM, de Mattos AM, Barry JM, et al. Renal transplantation across the ABO barrier using A2 kidneys. Transplantation 1999;67:1319-1324. (Pubitemid 29252406)
58. Nelson PW, Landreneau MD, Luger AM, et al. Ten-year experience in transplantation of A2 kidneys into B and O recipients. Transplantation 1998;65:256-260. (Pubitemid 28099221)
59. Sorensen JB, Grant WJ, Belnap LP, et al. Transplantation ofABOgroupA2 kidneys fromliving donors into group O and B recipients Am J Transplant 2001 1 296-299
60. Gloor JM, Lager DJ, Fidler ME, et al. A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005;80:1572-1577. (Pubitemid 43005868)
61. Ishida H, Koyama I, Sawada T, et al. Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation. Transplantation 2000;70:681-685. (Pubitemid 30659655)
62. Genberg H, Hansson A, Wernerson A, et al. Pharmacodynamics of rituximab in kidney allotransplantation. AmJ Transplant 2006;6:2418-2428. (Pubitemid 44359429)
63. Tyden G, Genberg H, Tollemar J, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009;87:1325-1329.
64. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004;77:542-548. (Pubitemid 38282809)
65. Segev DL, Simpkins CE, Warren DS, et al. ABO incompatiblehigh-titer renal transplantation without splenectomy or anti-CD20 treatment, Am J Transplant 2005;5:2570-2570.
66. Montgomery RA. Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols. Am J Transplant 2010;10:449-457.
67. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004;15:3256-3262. (Pubitemid 39578859)
68. Alachkar N, Lonze BE, Zachary AA, et al. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012;94:165-171.
69. Pins MR, Saidman SL, Cosimi AB, et al. Accelerated acute rejection of an apparent A2 renal allograft in an O recipient: report of a case with flow cytometric analysis. Transplantation 1997;63:984- 988.
70. Rydberg L, Breimer ME, Brynger H, et al. ABO-incompatible kidney transplantation (A2 toO).Qualitative and semiquantitative studies of the humoral immune response against different blood group A antigens. Transplantation 1990;49:954-960. (Pubitemid 20171967)
71. Montgomery JR, Berger JC, Warren DS, et al. Outcomes of ABO-incompatible kidney transplantation in the United States. Transplantation 2012;93:603-609.
72. Slapak M, Naik RB, Lee HA. Renal transplant in a patient with major donor-recipient blood group incompatibility: reversal of acute rejection by the use of modified plasmapheresis. Transplantation 1981;31:4-7. (Pubitemid 11155042)
73. Mohacsi P, Rieben R, Sigurdsson G, et al. Successful management of a B-type cardiac allograft into an O-typeman with 3(1/2)-year clinical follow-up. Transplantation 2001;72:1328-1330. (Pubitemid 33026618)
74. Pierson RN, 3rd, Loyd JE, Goodwin A, et al. Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy. Transplantation 2002;74:79-84. (Pubitemid 34779215)
75. Mierzejewska B, Durlik M, Lisik W, et al. Current approaches in national kidney paired donation programs. Ann Transplant 2013;18:112-124.
76. Wallis CB, Samy KP, Roth AE, et al. Kidney paired donation. Nephrol Dial Transplant 2011;26:2091-2099.
77. Ferrari P, Hughes PD, Cohney SJ, et al. ABO-incompatible matching significantly enhances transplant rates in kidney paired donation. Transplantation 2013;96:821-826.
78. Clausen H, Hakomori S. ABH and related histo-blood group antigens; immunochemical differences in carrier isotypes and their distribution Vox Sang 1989 561-20
79. Kobata A, Ginsburg V. Oligosaccharides of human milk. I. Isolation and characterization. Arch Biochem Biophys 1969;130:509-513.
80. Lundblad A, Hallgren P, Rudmark A, et al. Structures and serological activities of three oligosaccharides isolated fromurines of nonstarved secretors and fromsecretors on lactose diet. Biochemistry 1973;12:3341-3345.
81. Szulman AE. The histological distribution of blood group A and B substances in man. J Exp Med 1960;111:785-800.
82. Watkins W. The ABO blood group system, historical background Transfus Med 2001 11 243-265
83. Varki A, Cummings RD, Esko JD, et al. Editors. Essentials of glycobiology. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2009.
84. de Graffenried CL, Bertozzi CR.The roles of enzyme localization and complex formation in glycan assembly within the Golgi apparatus. Curr Opin Cell Bio 2004;16:356-363. (Pubitemid 38903141)
85. Tu L, Banfield DK. Localization of Golgi-resident glycosyltransferases. Cell Mol Life Sci 2010;67:29-41.
86. Finne J. Identification of the blood-group ABH-active glycoprotein components of human erythrocyte membrane. Eur J Biochem 1980;104:181-189. (Pubitemid 10099519)
87. Fredriksson SA, Podbielska M, Nilsson B, et al. ABH blood group antigens in N-glycan of human glycophorin A. Arch Biochem Biophys 2010;498:127-135.
88. Podbielska M, Fredriksson SA, Nilsson B. ABH blood group antigens in O-glycans of human glycophorin A. Arch Biochem Biophys 2004;429:145-153. (Pubitemid 39093824)
89. Matsui T, Titani K ABO(H) blood group expression on circulating glycoproteins.MethodsMolMed 1998 9 235-245
90. Bryne M, Lilleholt S, Thrane PS, et al. Distribution of blood-group-related carbohydrate antigens on oral endothelial cells. Histochem J 1993;25:339-347. (Pubitemid 23156145)
91. Gehrie EA, Cates JM, Nian H, et al. Blood Group A antigen expression on cardiac endothelium is highly individualized: possible implications for transplantation. Cardiovasc Pathol 2013;22:251-256.
92. Ravn V, Dabelsteen E. Tissue distribution of histo-blood group antigens. APMIS 2000;108:1-28. (Pubitemid 30090251)
93. Tasaki M, Yoshida Y, Miyamoto M, et al. Identification and characterization of major proteins carrying ABO blood group antigens in the human kidney. Transplantation 2009;87:1125-1133.
94. Kelly RJ, Rouquier S, Giorgi D, et al. Sequence and expression of a candidate for the human Secretor blood group alpha(1,2)fucosyltransferase gene (FUT2). Homozygosity for an enzymeinactivating nonsense mutation commonly correlates with the non-secretor phenotype. J Biol Chem 1995;270:4640-4649.
95. Larsen RD, Ernst LK, Nair RP, et al.Molecular cloning, sequence, and expression of a human GDPL- fucose:beta-D-galactoside 2-alpha-L- fucosyltransferase cDNA that can form the H blood group antigen Proc Natl Acad Sci USA 1990 87 6674-6678
96. Rouquier S, Lowe JB, Kelly RJ, et al.Molecular cloning of a human genomic region containing theH blood group alpha(1,2)fucosyltransferase gene and twoHlocus-relatedDNA restriction fragments. Isolation of a candidate for the human Secretor blood group locus. J Biol Chem 1995;270:4632- 4639.
97. Yamamoto F, Clausen H,White T, et al.Molecular genetic basis of the histo-blood group ABO system Nature 1990 345 229-233
98. Yamamoto F, NcNeill PD, Hakomori S. Human histo-blood group A2 transferase coded by A2 allele, one of the A subtypes, is characterized by a single base deletion in the coding sequence, which results in an additional domain at the carboxyl terminal. Biochem Biophys Res Commun 1992;187:366-374.
99. Amado M, Almeida R, Schwientek T, Clausen H. Identification and characterization of large galactosyltransferase gene families: galactosyltransferases for all functions. Biochim Biophys Acta 1999;1473:35-53.
100. Hennet T.The galactosyltransferase family CellMol Life Sci 2002 59 1081-1095
101. Togayachi A, Sato T, Narimatsu H. Comprehensive enzymatic characterization of glycosyltranferases with a b3GT or b4GTmotif.Methods Enzymol 2006 416 91-101
102. Holgersson J, Lofling J. Glycosyltransferases involved in type 1 chain and Lewis antigen biosynthesis exhibit glycan and core chain specificity. Glycobiology 2006l;16:584-593. (Pubitemid 43985499)
103. Zhou D, Henion T, Jungalwala FB, et al. The b1,3-galactosyltransferase b3GalT-V is a stage-specific embryonic antigen-3 (SSEA-3) synthase. J Biol Chem 2000;275:22631-22634. (Pubitemid 30646144)
104. Yang Z, Bergstrom J, Karlsson KA. Glycoproteins with Gal alpha 4Gal are absent from human erythrocyte membranes, indicating that glycolipids are the sole carriers of blood group P activities. J Biol Chem 1994;269:14620-14624.
105. Ju T, Brewer K, D'Souza A, et al. Cloning and expression of human core 1 b1,3galactosyltransferase. J Biol Chem 2002;277:178-186. (Pubitemid 34952043)
106. Ly M, Laremore TN, Linhardt RJ. Proteoglycomics: recent progress and future challenges. OMICS 2010;14:389-399.
107. Osman N, McKenzie IFC, Mouhtouris E, et al. MS. Switching amino-terminal cytoplasmic domains of a(1,2)fucosyltransferase and a(1,3)galactosyltransferase alters the expression ofHsubstance and Gala(1,3)Gal. J Biol Chem 1996;271:33105-33109.
108. Deutscher SL, Nuwayhid N, Stanley P, et al. Translocation across Golgi vesicel membranes: a CHO glycosylationmutant deficient in CMP-sialic acid transport. Cell 1984;39:295-299. (Pubitemid 15191212)
109. Svensson L, Hult AK, Stamps R, et al. Forssman expression on human erythrocytes: biochemical and genetic evidence of a new histo-blood group system. Blood 2013;121:1459-1468.
110. Oriol R, Le Pendu J, Mollicone R. Genetics of ABO, H, Lewis, X and related antigens. Vox Sang 1986;51:161-171. (Pubitemid 17197721)
111. Gillard BK, Jones MA, Marcus DM. Glycosphingolipids of human umbilical vein endothelial cells and smoothmuscle cells. Arch Biochem Biophys 1987;256:435-445. (Pubitemid 17128519)
112. Gillard BK, Jones MA, Turner AA, et al. Interferon-g alters expression of endothelial cell-surface glycosphingolipids. Arch Biochem Biophys 1990;279:122-129. (Pubitemid 20149782)
113. Nosaka M, Ishida Y, Tanaka A, et al. Aberrant expression of histo-blood group A type 3 antigens in vascular endothelial cells in inflammatory sites. J Histochem Cytochem 2008;56:223-231. (Pubitemid 351272994)
114. Mikhalski D, Wissing KM, Ghisdal L, et al. Cold ischemia is amajor determinant of acute rejection and renal graft survival in the modern era of immunosuppression. Transplantation 2008;85:S3-S9. (Pubitemid 351522769)
115. Bjork S, Breimer ME, Hansson GC, et al. Structures of blood group glycosphingolipids of human small intestine. A relation between the expression of fucolipids of epithelial cells and the ABO, Le and Se phenotype of the donor. J Biol Chem 1987;262:6758-6765.
116. Finne J, BreimerME, Hansson GC, et al. Novel polyfucosylated N-linked glycopeptides with blood group A, H, X, and Y determinants from human small intestinal epithelial cells. J Biol Chem 1989;264:5720-5735. (Pubitemid 19098034)
117. Holgersson J, Jovall PA, Samuelsson BE, et al. Blood group type glycosphingolipids of human kidneys. Structural characterization of extended globo-series compounds. Glycoconj J 1991;8:424- 433.
118. Hayashi S, Noguchi K, Yagihashi A, et al. Expression of blood group antigen (A,B,H, Lea,Leb) on liver allografts. Transplant Proc 1992;24:2567-2568. (Pubitemid 23011600)
119. Samuelsson BE, Magnusson S, Rydberg L, et al. Structural characterization of blood group A glycolipids in blood group A liver tissue in situ perfused with O blood: the dominating presence of type 1 core chain A antigens. Xenotransplantation 2006;13:160-165.
120. Kumasaki T, Yoshida A. Biochemical evidence that secretor gene, Se, is a structural gene encoding a specific fucosyltransferase. Proc Natl Acad Sci USA 1984;81:4193-4197. (Pubitemid 14054547)
121. Oriol R, Danilovs J, Hawkins BR. A new genetic model proposing that the Se gene is a structural gene closely linked to the H gene. Am J Hum Gen 1981;33:421-431. (Pubitemid 11026794)
122. Thorpe SJ, Hunt B, Yacoub M. Expression of ABH blood group antigens in human heart tissue and its relevance to cardiac transplantation. Transplantation 1991;51:1290-1295.
123. Breimer ME. Tissue specificity of glycosphingolipids as expressed in pancreas and small intestine of blood group A and B human individuals. Arch Biochem Biophys 1984;228:71-85. (Pubitemid 14175775)
124. Ernst C,Thurin J, Atkinson B, et al.Monoclonal antibody localization of A and B isoantigens in normal andmalignant fixed human tissues AmJ Pathol 1984 117 451-461
125. Ito N, Nishi K, Kawahara S, et al. Difference in the ability of blood group-specific lectins and monoclonal antibodies to recognize the ABH antigens in human tissues. Histochem J 1990;22:604-614. (Pubitemid 20368330)
126. Ito N, Nishi K, Nakajima M, et al. Histochemical localization and analysis of blood group-related antigens in human pancreas using immunostaining with monoclonal antibodies and exoglycosidase digestion. J Histochem Cytochem 1990;38:1331-1340. (Pubitemid 20266132)
127. Rieben R, Buchs JP, Fluckiger E, et al. Antibodies to histo-blood group substances A and B: agglutination titers, Ig class, and IgG subclasses in healthy persons of different age categories. Transfusion 1991;31:607-615.
128. Springer GF, Williamson P, Readler BL. Blood group active gram-negative bacteria and higher plants. Ann N Y Acad Sci 1962;97:104-110.
129. Springer GF. Influenza virus vaccine and blood group A-like substances. Transfusion 1963;3:233-236.
130. Rydberg L, Breimer ME, Holgersson J, et al Characterisation of the anti-A antibody response following an ABO incompatible (A2 to O) kidney transplantation. Mol Immunol 1992 29 547-560
131. Rydberg L, Nyberg G, Attman PO, et al. Characterization of the anti-A antibody binding in an ABOincompatible living donor renal transplantation. Nephrol Dial Transplant 1994;9:1162-1165. (Pubitemid 24254086)
132. Lindberg L, Johansson SM, Liu J, et al Is there a clinical need for a diagnostic test allowing detection of chain type-specific anti-A and anti-B? Transfusion 2011 51 494-503
133. Lindberg L, Theinert K, Liu J, et al. Adsorption of chain type-specific ABO antibodies on Sepharoselinked A and B tetrasaccharides. Transfusion 2012;52:2356-2367.
134. Kumlien G, Ullstrom L, Losvall A, et al. Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies. Transfusion 2006;46:1568-1575. (Pubitemid 44326333)
135. ChopekMW, SimmonsRL, Platt JL.ABO-incompatible renal transplantation: initial immunopathologic evaluation Transplant Proc 1987 19 4553-4557 (Pubitemid 18049660)
136. Bach FH, Ferran C, Hechenleitner P, et al. Accommodation of vascularized xenografts: Expression of "protective genes" by donor endothelial cells in a hostTh2 cytokine environment. Nature Med 1997;3:196-204. (Pubitemid 27064705)
137. Ding JW, Zhou T, Ma L, et al. Expression of complement regulatory proteins in accommodated xenografts induced by anti-a-Gal IgG1 in a rat-to-mousemodel. Am J Transplant 2008;8:32-40.
138. Dalmasso AP, Benson BA, Johnson JS, et al. Resistance against the membrane attack complex of complement induced in porcine endothelial cells with a Gala(1-3)Gal binding lectin: upregulation of CD59 expression. J Immunol 2000;164:3764-3773. (Pubitemid 30169833)
139. Salama AD, Delikouras A, Pusey CD, et al. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. AmJ Transplant 2001;1:260-269. (Pubitemid 33674170)
140. Park WD, Grande JP, Ninova D, et al. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003;3:952-960. (Pubitemid 36917540)
141. Medawar PB. Transplantation of tissues and organs: introduction. BrMed Bull 1965;21:97-99.
142. Koestner SC, Kappeler A, Schaffner T, et al. Histo-blood group change of the graft from B to O after ABOmismatched heart transplantation. Lancet 2004;363:1523-1525. (Pubitemid 38596831)
143. Lagaaij EL, Cramer-Knijnenburg GF, van Kemenade FJ, et al. Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet 2001;357:33-37. (Pubitemid 32056499)
144. Tanabe T, Ishida H, Horita S, et al. Endothelial chimerism after ABO-incompatible kidney transplantation. Transplantation 2012;93:709-716.
145. Yu PB, Holzknecht ZE, Bruno D, et al. Modulation of natural IgM binding and complement activation by natural IgG antibodies: a role for IgG anti-Gal alpha1-3Gal antibodies. J Immunol 1996;157:5163-5168. (Pubitemid 126449600)
146. Krishnan NS, Fleetwood P, Higgins RM, et al. Application of flow cytometry to monitor antibody levels in AB0 incompatible kidney transplantation. Transplantation 2008;86:474-477.
147. Stussi G, Huggel K, Lutz HU, et al. Isotype-specific detection of ABO blood group antibodies using a novel flow cytometricmethod. Br J Haematol 2005;130:954-963. (Pubitemid 43899736)
148. Yurugi K, Kimura S, Ashihara E, et al. Rapid and accurate measurement of anti-A/B IgG antibody in AB0-unmatched living donor liver transplantation by surface plasmon resonance. TransfusMed 2007;17:97-106. (Pubitemid 46558252)
149. Frame T, Carroll T, Korchagina E, et al. Synthetic glycolipid modification of red blood cell membranes. Transfusion 2007;47:876-882. (Pubitemid 46669002)
150. Hult AK, Frame T, Chesla S, et al. Flow cytometry evaluation of red blood cells mimicking naturally occurring ABO subgroups aftermodification with variable amounts of function-spacer-lipid A and B constructs. Transfusion 2012;52:247-251.
151. Matic G, Hofmann D, Winkler R, et al. Removal of immunoglobulins by a protein A versus an antihuman immunoglobulin G-based system: evaluation of 602 sessions of extracorporeal immunoadsorption. Artif Organs 2000;24:103-107. (Pubitemid 30408703)
152. Bensinger WI, Baker DA, Buckner CD, et al. Immunoadsorption for removal of A and B blood-group antibodies. N Engl JMed 1981;304:160-162. (Pubitemid 11163002)
153. Bannett AD, Bensinger WI, Raja R, et al. Immunoadsorption and renal transplant in two patients with amajor ABO incompatibility. Transplantation 1987;43:909-911. (Pubitemid 17084274)
154. Mendez R, Sakhrani L, Aswad S, et al. Successful living-related ABO incompatible renal transplant using the BIOSYNSORB immunoadsorption column. Transplant Proc 1992;24:1738-1740.
155. Blomberg L, Bratt T, Chester MA, et al. Improved removal of anti-A and anti-B antibodies from plasma using blood-group-active haptens. Vox Sang 1993;65:126-135. (Pubitemid 23239638)
156. Rieben R, Korchagina EY, von Allmen E, et al. In vitro evaluation of the efficacy and biocompatibility of new, synthetic ABO immunoabsorbents. Transplantation 1995;60:425-430.
157. Solovan JC, Oh HI, Alikhani A, et al. Synthetic blood group antigens for anti-A removal device and their interaction withmonoclonal anti-A IgM. Transplant Immunol 2006;16:245-249. (Pubitemid 44809911)
158. Genberg H, Kumlien G, Wennberg L, et al. The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation. Nephrol Dial Transplant 2011;26:2394-2400.
159. Genberg H, Kumlien G, Wennberg L, et al. Isoagglutinin adsorption in ABO-incompatible transplantation. Transfus Apher Sci 2010;43:231-235.
160. McKane W, Lee J, Preston R, et al. Polymorphism in the human anti-pig natural antibody repertoire. Implications for antigen-specific immunoadsorption. Transplantation 1998;66:626- 633. (Pubitemid 28433846)
161. Lofling JC, Hauzenberger E, Holgersson J. Absorption of anti-blood groupAantibodies onP-selectin glycoprotein ligand-1/immunoglobulin chimeras carrying blood group A determinants: core saccharide chain specificity of the Se andHgene encoded alpha1,2 fucosyltransferases in different host cells. Glycobiology 1 2002 12 173-182
162. Lindberg L, Liu J, Holgersson J. Engineering of therapeutic and diagnostic o-glycans on recombinant mucin-type immunoglobulin fusion proteins expressed in CHO cells. In: Beck A, editor. Glycosylation engineering of biopharmaceuticals: methods and protocols, methods in molecular biology. New York: Springer. Science+Business Media; 2013. 988, pp. 3-17.
163. Romano EL, Soyano A, Linares J, et al. Neutralization of ABO blood group antibodies by specific oligosaccharides. Transplant Proc 1987;19:4426-4430. (Pubitemid 18049632)
164. Romano EL, Soyano A,Montano RF, et al. Treatment of ABO hemolytic diseasewith synthetic blood group trisaccharides. Vox Sang 1994;66:194-199. (Pubitemid 24103655)
165. Oliver C, Blake D, Henry S. In vivo neutralization of anti-A and successful transfusion of A antigenincompatible red blood cells in an animal model. Transfusion 2011;51:2664-2675.
166. Simon PM, Neethling FA, Taniguchi S, et al. Intravenous infusion of Galalpha1-3Gal oligosaccharides in baboons delays hyperacute rejection of porcine heart xenografts. Transplantation 1998;65:346-353. (Pubitemid 28095961)
167. Ye Y, Neethling FA, Niekrasz M, et al. Evidence that intravenously administered alpha-galactosyl carbohydrates reduce baboon serum cytotoxicity to pig kidney cells (PK15) and transplanted pig hearts. Transplantation 1994;58:330-337. (Pubitemid 24252287)
168. Diamond LE, ByrneGW, Schwarz A, et al. Analysis of the control of the anti-galimmune response in anon-human primate by galactose alpha1-3 galactose trisaccharide-polyethylene glycol conjugate. Transplantation 2002;73:1780-1787. (Pubitemid 34655254)
169. Katopodis AG, Warner RG, Duthaler RO, et al. Removal of anti-Galalpha1,3Gal xenoantibodieswith an injectable polymer. J Clin Invest 2002;110:1869-1877. (Pubitemid 36076494)
170. Teranishi K, Gollackner B, Buhler L, et al. Depletion of anti-gal antibodies in baboons by intravenous therapy with bovine serum albumin conjugated to gal oligosaccharides. Transplantation 2002;73:129-139. (Pubitemid 34094699)